PureTech Health (PRTC)
17.88
0.81 (4.75%)
At close: Jan 15, 2025, 9:30 AM
undefined% (undefined)
| Bid | 17.9 |
| Market Cap | 428.08M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3 |
| PE Ratio (ttm) | -5.96 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 18.12 |
| Volume | 3,149 |
| Avg. Volume (20D) | 4,652 |
| Open | 17.59 |
| Previous Close | 17.07 |
| Day's Range | 17.59 - 17.88 |
| 52-Week Range | 17.00 - 34.00 |
| Beta | undefined |
About PRTC
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platfo...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 16, 2020
Employees 90
Stock Exchange NASDAQ
Ticker Symbol PRTC
Website https://www.puretechhealth.com
Analyst Forecast
According to 1 analyst ratings, the average rating for PRTC stock is "Buy." The 12-month stock price forecast is $45, which is an increase of 151.68% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago ·
Source
+8.85%
PureTech Health shares are trading higher after th...
Unlock content with
Pro Subscription
4 months ago ·
Source
-6%
PureTech Health shares are trading lower after the company reported a year-over-year decrease in H1 financial results.
1 week ago · businesswire.com
PureTech Appoints UBS as UK Corporate BrokerBOSTON--(BUSINESS WIRE)--PureTech Appoints UBS as UK Corporate Broker.
